NSCLC, STAGE III

Clinical trials for NSCLC, STAGE III explained in plain language.

Never miss a new study

Get alerted when new NSCLC, STAGE III trials appear

Sign up with your email to follow new studies for NSCLC, STAGE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 4 Not yet recruiting 1 Not yet finished but already full! 2 Completed 1

Targeted drug trial aims to extend remission for Tough-to-Treat lung cancer

Disease control Not yet recruiting

This study is testing whether adding the targeted drug ensartinib after standard chemoradiation can better control advanced, inoperable lung cancer in patients with a specific genetic change (ALK mutation). It will involve about 45 patients who have completed initial treatment wi…

Matched conditions: NSCLC, STAGE III

Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control

Last updated Mar 05, 2026 13:59 UTC

NSCLC, STAGE III

Get alerted when new NSCLC, STAGE III trials appear

Targeted drug trial aims to extend remission for Tough-to-Treat lung cancer